Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132961 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL335170 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL983600 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL981267 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL493130 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL22288118 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL63140 | 1.00 | — | — | |
| SCHEMBL16114084 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL982461 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL983618 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367244-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2024-05-15 | — | — | EP | claimed |
| EP-4161596-A1 | NANOFIBROUS MATERIAL PARTICULARLY FOR TOPICAL USE IN THERAPIES | Univerzita Karlova (CZ) | 2023-04-12 | — | — | EP | claimed |
| WO-2023280190-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2023-01-12 | — | — | WO | claimed |
| EP-3448865-B1 | LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-09-04 | — | — | EP | claimed |
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | claimed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | claimed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | claimed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | claimed |
| EP-2527351-B1 | Lipophosphonoxins, method of their preparation and use | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2013-12-11 | — | — | EP | claimed |
| EP-2558466-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | The Regents of the University of California (US) | 2013-02-20 | — | — | EP | claimed |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | claimed |
| WO-2011130557-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | claimed |
| CN-1245153-C | Vitamin A liposome and its preparation method | SHANGHAI JIAHUA UNION CO LTD (CN) | 2006-03-15 | — | — | CN | claimed |
| CN-1301572-A | Adjuvant composition for vaccine | SHANGHAI BIOLOG PRODUCT I (CN) | 2001-07-04 | — | — | CN | claimed |
| EP-0316618-B1 | Multilayer flat light sensitive registration material | BASF AG (DE) | 1994-08-17 | — | — | EP | claimed |
| CN-114127057-B | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118302407-A | Carbonyl compound, method for producing isocyanate compound, and isocyanate composition | 旭化成株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-4118368-A | DERIVATIVES OF 2,6-DIMETHYL-2,6-DIALKYL-4-AMINO-4-CARBOXYLATE-PIPERIDINES | SANKYO COMPANY LIMITED (JP) | 1978-10-03 | — | — | US | disclosed |
| US-4094801-A | ADDITIVES FOR LUBRICANTS AND FUELS, CORROSION RESISTANT COATINGS FOR METALS | THE LUBRIZOL CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4012504-A | Iodine mineral oil solution for preventing bovine mastitis | VELVET CHEMICAL CO. (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | THRB 1729/4885HTT 1612/4885MEN1 4546/4885 |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | THRB 1729/4885HTT 1612/4885MEN1 4546/4885 |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | THRB 1729/4885HTT 1612/4885MEN1 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.